The role of secondary cytoreductive surgery in the treatment of patients with recurrent epithelial ovarian carcinoma

Cancer

Volumn 88, Issue 1, 2000, Pages 144-153

  Eisenkop, Scott M ^a   Friedman, Richard L ^a   Spirtos, Nick M ^b  

^a Womens' Cancer Ctr: Encino Tarzana   (United States)

^b Womens' Cancer Center: Palo Alto   (United States)

Author keywords

Cytoreductive surgery; Prognosis; Recurrent ovarian carcinoma; Survival

Indexed keywords

CA 125 ANTIGEN; CISPLATIN; PACLITAXEL; TOPOTECAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURGERY; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MULTIVARIATE ANALYSIS; OVARY CARCINOMA; PRIORITY JOURNAL; RECURRENT CANCER; REOPERATION; SURVIVAL TIME; TREATMENT OUTCOME; TUMOR VOLUME;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; OVARIAN NEOPLASMS; PROSPECTIVE STUDIES; REOPERATION; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 0033957510     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<144::AID-CNCR20>3.0.CO;2-X     Document Type: Article

References (25)

1. Hoskins WJ. Primary cytoreductive surgery for advanced disease. In: Gershenson DM, Mcguire WP, editors. Ovarian cancer. New York: Churchill Livingstone Inc., 1998: 66-70.
2. Bristow RE, Lagasse LD, Karlan BY. Secondary surgical cytoreduction for advanced epithelial ovarian cancer: patient selection and review of the literature. Cancer 1996;78:2049-62.
3. Swenerton K, Muss HB, Robinson EG. Salvage chemotherapy for refractory disease. In: Gershenson DM, Mcguire WP, editors. Ovarian cancer. New York: Churchill Livingstone Inc., 1998:169-94.
4. Markman M, Reichman B, Hakes T, Jones W, Lewis JL Jr., Rubin S, et al. Responses to second-line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. J Clin Oncol 1991;9: 1801-5.
5. Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J, et al. Continued chemosensitivity to cisplatin/carboplatin in ovarian carcinoma despite treatment with multiple prior platinum based regimens. Gynecol Oncol 1997;65:434-6.
6. Eltabbakh GH, Piver SP, Hempling RE, Recio FO, Blumenson LE. Prolonged disease-free survival by maintenance chemotherapy among patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol 1998;7:190-5.
7. Keldsen N, Madsen EL, Havsteen H, Kamby C, Laursen L, Sandberg E. Oral Treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. Gynecol Oncol 1998;69:100-2.
8. Swisher EM, Mutch DG, Rader JS, Elbendary A, Herzog JA. Topotecan in platinum-and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997;66:480-6.
9. Omura GA, Brady MF, Delmore JE. A randomized trial of paclitaxel at two dose levels and filgrastim at two dose levels in platinum pretreated epithelial ovarian cancer: a Gynecologic Oncology Group, SWOG, NCCTG, and ECOG study [abstract 755]. Proc Am Soc Clin Oncol 1996;15:280.
10. Berek JS, Hacker NF, Lagasse LD, Nieberg RK, Elashoff RM. Survival of patients following secondary cytoreductive surgery in ovarian cancer. Obstet Gynecol 1983;61:189-93.
11. Morris M, Gershenson DM, Wharton TJ, Copeland LJ, Edwards CL, Stringer CA. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer. Gynecol Oncol 1989;34: 334-8.
12. Janicke F, Holscher M, Kuhn W, von Hugo R, Pache L, Siewert JL, et al. Radical surgical procedure improves survival time in patients with recurrent ovarian cancer. Cancer 1992;70:2129-36
13. Vaccarello L, Rubin SC, Vlamis V, Wong G, Jones WB, Lewis JL Jr. Cytoreductive surgery in ovarian cancer patients with a documented previously complete surgical response. Gynecol Oncol 1995;57:61-5.
14. Eisenkop SM, Friedman RL, Wang H. Secondary cytoreductive surgery for recurrent ovarian cancer: a prospective study. Cancer 1995;76:1606-14.
15. Deppe G, Maliviya VK, Malone JM. Debulking surgery for ovarian cancer with the Cavitron Ultrasonic Surgical Aspirator (CUSA)-A preliminary report. Gynecol Oncol 1988;31: 223-6.
16. Eisenkop SM, Nalick RH, Teng NNH. Modified posterior exenteration for ovarian cancer. Obstet Gynecol 1991; 78:879-85.
17. Eisenkop SM, Nalick RH, Wang H Teng NN. Peritoneal implant elimination during cytoreductive surgery for ovarian cancer: impact on survival. Gynecol Oncol 1993;51:224-9.
18. Montz FJ, Schlaerth JB, Berek JS. Resection of diaphragmatic peritoneum and muscle: role in cytoreductive surgery for ovarian cancer. Gynecol Oncol 1989;35:338-40.
19. Morrow CP, Curtin JP. Surgery for ovarian neoplasia. In: Gynecologic cancer surgery. New York: Churchill Livingstone Inc., 1996:627-716.
20. Spirtos NM, Gross GM, Freddo JL, Ballon SC. Cytoreductive surgery in advanced epithelial cancer of the ovary: the impact of aortic and pelvic lymphadenectomy. Gynecol Oncol 1995;56:3453-352.
21. Eisenkop SM, Friedman RL, Wang H. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study. Gynecol Oncol 1998;69:103-6.
22. Brewer CA, Chan J, Kurosaki T, Berman M. Radical hysterectomy with an endoscopic stapler. Gynecol Oncol 1998;71: 50-2.
23. Eisenkop SM, Spirtos NM, Montag TW, Nalick RH, Wang H. The impact of suhspecialty training on the management of advanced ovarian cancer. Gynecol Oncol 1992;47:203-9.
24. Rubin SC, Benjamin I, Berek JS. Secondary cytoreductive surgery. In: Gershenson DM, Mcguire WP, editors. Ovarian cancer. New York: Churchill Livingstone Inc., 1998:101-13.
25. Hoskins WJ, Bundy BN, Thigpen JT, Omura GA. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 1992;47:167-71.